| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $149.4M | — | +5.6% |
| Cost of Revenue | $14.5M | — | -19.2% |
| R&D Expense | $2.7M | — | -31.5% |
| SG&A Expense | $49.3M | — | +5.1% |
| Operating Income | $73.2M | — | +15.6% |
| Pre-tax Income | $84.2M | — | +18.2% |
| Income Tax | $20.5M | — | +40.9% |
| Net Income | $63.7M | — | +12.3% |
| EPS (Basic) | $0.52 | — | +10.6% |
| EPS (Diluted) | $0.50 | — | +11.1% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $755.9M | +6.6% | +30.2% |
| Accounts Receivable | $130.8M | +3.4% | +83.6% |
| Inventory | $34.9M | -6.0% | +76.6% |
| Current Assets | $940.4M | +5.2% | +37.1% |
| Total Assets | $1.15B | +4.0% | +26.3% |
| Current Liabilities | $132.4M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | $59.6M | — | -0.8% |
| Capital Expenditures | $27K | — | — |
| Investing Cash Flow | -$27K | — | — |
| Financing Cash Flow | -$12.9M | — | -520.7% |
| Free Cash Flow | $59.6M | — | -0.8% |
| +18.6% |
| Total Liabilities | $134.9M | -9.9% | +17.7% |
| Stockholders' Equity | $1.01B | +6.1% | +27.5% |